摘要
目的雷珠单抗对新生血管性青光眼患者血清、房水白细胞介素-6(IL-6)及血管内皮生长因子(VEGF)水平影响。方法收集浙江省中医药大学附属第一医院眼科新生血管性青光眼患者66例,随机分为实验组与对照组,各33例。对照组局部给予阿托品、糖皮质激素等常规治疗,采用全视网膜光凝术(panretina/photocoagulation,PRP);实验组在对照组基础上给予雷珠单抗注射液,2组均治疗4次。比较治疗前后2组患者血清及房水IL-6、VEGF及眼压变化。结果治疗后2组患者的血清及房水IL-6、VEGF水平降低,眼压降低(P<0.05),与对照组相比,实验组血清及房水IL-6、VEGF水平较低,眼压较低(P<0.05)。结论雷珠单抗能够有效治疗新生血管性青光眼,降低眼压,推测其机制可能与降低新生血管性青光眼患者血清及房水IL-6、VEGF水平有关。
Objective To investigate the effect of ranibizumab on the serum and aqueous humor levels of IL-6 and VEGF in neovascular glaucoma patients. Methods 66 neovascular glaucoma patients from our hospital were selected and randomly divided into the control group and experimental group with 33 cases in each group. ＇ The control group were treated by atropine, glucocorticoid and partretina/photocoagulation （PRP）. The experimental group were treated on the basis of the control group with monoclonal antibody injection. Two groups were treated for four times. The aqueous IL-6, VEGF and intraocular pressure were tested and compared pre-and post-treatment. Results Compared with pre-treatment in two groups, the IL-6 and VEGF levels in serum and aqueous humor were lower （P 〈 0. 05 ）, the intraocular pressure were lower（ P 〈 0. 05 ）. Compared with the control group post-treatment, the IL-6 and VEGF levels in serum and aqueous humor were lower （ P 〈 0. 05 ）, the intraocular pressure were lower （ P 〈 0.05 ）. Conclusion The results suggest that the mechanism may be related to the decrease of serum levels of IL-6 and VEGF in the serum and aqueous humor of the neovascular glaucoma patients.
出处
《中国生化药物杂志》
CAS
2016年第2期151-153,共3页
Chinese Journal of Biochemical Pharmaceutics
基金
浙江省中医药科技计划项目(2015ZA086)
